Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma-Reference-Cited by-同舟云学术

Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

Published:2018-03 Issue:3 Volume:29 Page:724-730
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Herrera A.F.,Palmer J.,Martin P.,Armenian S.,Tsai N.-C.,Kennedy N.,Sahebi F.,Cao T.,Budde L.E.,Mei M.,Siddiqi T.,Popplewell L.,Rosen S.T.,Kwak L.W.,Nademanee A.,Forman S.J.,Chen R.

Funder

National Institutes of Health

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/29/3/724/24530893/mdx791.pdf

Reference23 articles.

1. How I treat relapsed and refractory Hodgkin lymphoma;Kuruvilla;Blood,2011

2. Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation;Perales;Biol Blood Marrow Transplant,2015

3. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial;Schmitz;Lancet,2002

4. Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin's lymphoma and Hodgkin's disease;Hertzberg;Ann Oncol,2003

5. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease;Josting;Ann Oncol,2002

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimizing salvage therapy for Hodgkin lymphoma: progress and future challenges;Expert Review of Hematology;2024-06-27

2. What is the best salvage therapy for Hodgkin lymphoma?;Current Opinion in Oncology;2024-06-20

3. The role of autologous stem-cell transplantation in classical Hodgkin lymphoma in the modern era;Seminars in Hematology;2024-06

4. Paradigm Shifts in Hodgkin Lymphoma Treatment: From Frontline Therapies to Relapsed Disease;American Society of Clinical Oncology Educational Book;2024-06

5. Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score–matched analysis;Blood Advances;2024-05-30